

Nolan A Wages

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3444242/publications.pdf>

Version: 2024-02-01

68
papers

1,172
citations

471509

17
h-index

477307

29
g-index

72
all docs

72
docs citations

72
times ranked

1060
citing authors

#	ARTICLE	IF	CITATIONS
1	Continual Reassessment Method for Partial Ordering. <i>Biometrics</i> , 2011, 67, 1555-1563.	1.4	144
2	Dose-finding design for multi-drug combinations. <i>Clinical Trials</i> , 2011, 8, 380-389.	1.6	81
3	A multi-peptide vaccine plus toll-like receptor agonists LPS or poly(I:CLC in combination with incomplete Freund's adjuvant in melanoma patients. , 2019, 7, 163.		59
4	Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 903-920.	0.8	54
5	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 118-128.	6.3	49
6	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
7	Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. , 2021, 9, e002273.		39
8	Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1189-1199.	4.2	38
9	Phase I/II adaptive design for drug combination oncology trials. <i>Statistics in Medicine</i> , 2014, 33, 1990-2003.	1.6	36
10	Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1201-1212.	4.2	36
11	Specifications of a continual reassessment method design for phase I trials of combined drugs. <i>Pharmaceutical Statistics</i> , 2013, 12, 217-224.	1.3	32
12	A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. <i>Statistics in Medicine</i> , 2015, 34, 3194-3213.	1.6	30
13	Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 33-43.	4.2	30
14	Implementation of adaptive methods in early-phase clinical trials. <i>Statistics in Medicine</i> , 2017, 36, 215-224.	1.6	29
15	Cervical Cancer in Women Aged 35 Years and Younger. <i>Clinical Therapeutics</i> , 2016, 38, 459-466.	2.5	27
16	Performance of toxicity probability interval based designs in contrast to the continual reassessment method. <i>Statistics in Medicine</i> , 2017, 36, 291-300.	1.6	26
17	Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma. <i>Cells</i> , 2021, 10, 3378.	4.1	24
18	Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. <i>Statistics in Medicine</i> , 2016, 35, 3760-3775.	1.6	23

#	ARTICLE	IF	CITATIONS
19	A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. <i>Contemporary Clinical Trials</i> , 2015, 41, 172-179.	1.8	21
20	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
21	Phase I design for completely or partially ordered treatment schedules. <i>Statistics in Medicine</i> , 2014, 33, 569-579.	1.6	19
22	Using the time-to-event continual reassessment method in the presence of partial orders. <i>Statistics in Medicine</i> , 2013, 32, 131-141.	1.6	17
23	pocrm: An R-package for Phase I trials of combinations of agents. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 112, 211-218.	4.7	17
24	A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial. <i>Pharmaceutical Statistics</i> , 2015, 14, 302-310.	1.3	16
25	A web tool for designing and conducting phase I trials using the continual reassessment method. <i>BMC Cancer</i> , 2018, 18, 133.	2.6	16
26	Shift models for dose-finding in partially ordered groups. <i>Clinical Trials</i> , 2019, 16, 32-40.	1.6	15
27	Performance of two-stage continual reassessment method relative to an optimal benchmark. <i>Clinical Trials</i> , 2013, 10, 862-875.	1.6	14
28	Tubular carcinoma of the breast: Institutional and SEER database analysis supporting a unique classification. <i>Breast Disease</i> , 2015, 35, 103-111.	0.8	14
29	Identifying a maximum tolerated contour in two-dimensional dose finding. <i>Statistics in Medicine</i> , 2017, 36, 242-253.	1.6	13
30	Practical designs for Phase I combination studies in oncology. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 150-166.	0.8	12
31	Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents. <i>Clinical Cancer Research</i> , 2017, 23, 7158-7164.	7.0	11
32	Designs for phase I trials in ordered groups. <i>Statistics in Medicine</i> , 2017, 36, 254-265.	1.6	11
33	Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1254-1262.	0.8	11
34	Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials experience. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1531-1539.	4.2	10
35	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1490855.	4.6	10
36	STAT RAD: Prospective Dose Escalation Clinical Trial of Single Fraction Scan-Plan-QA-Treat Stereotactic Body Radiation Therapy for Painful Osseous Metastases. <i>Practical Radiation Oncology</i> , 2020, 10, e444-e451.	2.1	10

#	ARTICLE	IF	CITATIONS
37	A web application for evaluating Phase I methods using a non-parametric optimal benchmark. <i>Clinical Trials</i> , 2017, 14, 553-557.	1.6	9
38	Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. <i>JCO Precision Oncology</i> , 2021, 5, 317-324.	3.0	9
39	Comments on "Competing designs for drug combination in phase I dose-finding clinical trials" by Mâ€šK. Riviere, F. Dubois, S. Zohar. <i>Statistics in Medicine</i> , 2015, 34, 18-22.	1.6	8
40	Recent developments in the implementation of novel designs for early-phase combination studies. <i>Annals of Oncology</i> , 2015, 26, 1036-1037.	1.2	8
41	Revisiting isotonic phase I design in the era of model-assisted dose-finding. <i>Clinical Trials</i> , 2018, 15, 524-529.	1.6	7
42	Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy. <i>Clinical Trials</i> , 2020, 17, 157-165.	1.6	7
43	MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 585551.	2.8	7
44	Multi-Institution Phase I/II Continual Re-Assessment Study to Identify the Optimal Dose of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2019, 134, 1535-1535.	1.4	7
45	Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols. <i>Contemporary Clinical Trials</i> , 2021, 108, 106517.	1.8	6
46	IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival. <i>American Journal of Surgical Pathology</i> , 2021, 45, 787-795.	3.7	6
47	Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood Advances</i> , 2021, , .	5.2	5
48	Tailoring early-phase clinical trial design to address multiple research objectives. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 95-102.	4.2	4
49	Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2021, 154, 41-47.	2.9	4
50	Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 333-347.	0.8	3
51	Flexible Phase Iâ€šII Design for Partially Ordered Regimens with Application to Therapeutic Cancer Vaccines. <i>Statistics in Biosciences</i> , 2020, 12, 104-123.	1.2	3
52	Coherence principles in intervalâ€šbased dose finding. <i>Pharmaceutical Statistics</i> , 2020, 19, 137-144.	1.3	3
53	Obtaining the Optimal Dose in Alcohol Dependence Studies. <i>Frontiers in Psychiatry</i> , 2012, 3, 100.	2.6	2
54	Strategic evaluation of interventions to prevent consequential late proctitis after prostate radiation therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 361-364.	3.4	2

#	ARTICLE	IF	CITATIONS
55	Clinical outcomes of helical conformal versus nonconformal palliative radiation therapy for axial skeletal metastases. <i>Practical Radiation Oncology</i> , 2017, 7, e479-e487.	2.1	2
56	Accuracy, Safety, and Reliability of Novel Phase I Designs Letter. <i>Clinical Cancer Research</i> , 2018, 24, 5482-5482.	7.0	2
57	Generalization of the time-to-event continual reassessment method to bivariate outcomes. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 635-647.	0.8	2
58	Efficient dose-finding for drug combination studies involving a shift in study populations. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100519.	1.1	2
59	Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trial. <i>Clinical Trials</i> , 2021, 18, 314-323.	1.6	1
60	Bleeding Risk of Low-Molecular Weight Heparin Vs Direct Oral Anticoagulant in Patients with Intracranial Tumors. <i>Blood</i> , 2018, 132, 2524-2524.	1.4	1
61	Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11452.	2.6	1
62	Impact of dose feasibility on the conduct of phase I trials of adoptive cell therapy. <i>Contemporary Clinical Trials Communications</i> , 2022, 25, 100877.	1.1	1
63	Change in parathyroid hormone levels from baseline predicts hypocalcemia following total or completion thyroidectomy. <i>Head and Neck</i> , 2022, , .	2.0	1
64	Adaptive Phase 1 Design in Radiation Therapy Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 493-499.	0.8	1
65	Comments on "A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials" by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui. <i>Statistics in Medicine</i> , 2014, 33, 2156-2158.	1.6	0
66	Evaluation of irrational dose assignment definitions using the continual reassessment method. <i>Clinical Trials</i> , 2019, 16, 665-672.	1.6	0
67	Reply to M. Ratain. <i>JCO Precision Oncology</i> , 2021, 5, 937-938.	3.0	0
68	Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. <i>Blood</i> , 2019, 134, 4027-4027.	1.4	0